EBITDA Margin % is calculated as EBITDA divided by its Revenue. Motus GI Holdings's EBITDA for the
three
months ended in Mar. 2024 was €-1.73 Mil. Motus GI Holdings's Revenue for the
three
months ended in Mar. 2024 was €0.06 Mil. Therefore, Motus GI Holdings's EBITDA margin for the quarter that ended in Mar. 2024 was -2,935.59%.
Motus GI Holdings (STU:7M4) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Motus GI Holdings EBITDA Margin % Related Terms
Motus GI Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Motus GI Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7M4 vs ABT, BSX, SYK: EBITDA Margin % Comparison
For the Medical Devices subindustry, Motus GI Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Motus GI Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Motus GI Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Motus GI Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Motus GI Holdings (STU:7M4) has a EBITDA Margin % of -2,935.59% as of Mar. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Motus GI Holdings and its competitors.
Is Motus GI Holdings' EBITDA Margin % too high?
Motus GI Holdings' current EBITDA Margin % is -2,935.59%. Overall, Motus GI Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Motus GI Holdings' EBITDA Margin % compare to ABT and BSX?
Motus GI Holdings' EBITDA Margin % of -2,935.59% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Motus GI Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Motus GI Holdings's current EBITDA Margin % is -2,935.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Motus GI Holdings stock overvalued right now?
Motus GI Holdings (STU:7M4) has a current EBITDA Margin % of -2,935.59%. The current EBITDA Margin % is -2,935.59%. Motus GI Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Motus GI Holdings (STU:7M4), the current EBITDA Margin % is -2,935.59% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs, and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy.
12GF Score
Get the complete analysis for STU:7M4
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7M4 has been successfully added to your 
